Clinical Trial

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Study acronym: ANDECA-HO
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body over time (pharmacokinetics/PK), and how it affects the body (pharmacodynamics/PD) in participants who have had a recent traumatic spinal cord injury.
Trial Details
NCT Number NCT07024407
Lead Sponsor Ashibio Inc
Conditions Heterotopic Ossification (HO)
Enrollment 10 participants
Start Date 2025-05-14
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-17